Clinical Trials Browser

Recurrence, Triple Negative Breast Neoplasms

NCT05309655 2026-03-16

CROWN

Phase NA Recruiting

90 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02455791 2026-03-09

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Phase NA Active not recruiting

43 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02945579 2026-03-09

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Phase NA Recruiting

120 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07136493 2026-03-05

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Phase NA Suspended

350 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07067138 2026-03-03

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Phase NA Recruiting

175 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02993068 2026-02-19

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase NA Suspended

5,200 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06744465 2026-02-17

NearWave Optical Molecular Monitoring

Phase NA Recruiting

15 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07226102 2026-02-04

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

Phase NA Withdrawn

BreastGynecologic

Genital Neoplasms, Female, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03017573 2026-02-03

SCANDARE

Phase NA Recruiting

1,050 enrolled

BreastGynecologicHead & NeckSarcoma

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Vulvar Neoplasms, Triple Negative Breast Neoplasms

NCT04959474 2026-01-23

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Phase NA Recruiting

80 enrolled

Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Triple Negative Breast Neoplasms

NCT02158507 2026-01-22

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Phase NA Completed

20 enrolled 10 charts

Breast

Triple Negative Breast Neoplasms

NCT06225505 2026-01-22

CUPCAKE

Phase NA Recruiting

450 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07357948 2026-01-22

WISH-OMICHIR

Phase NA Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06962163 2026-01-12

EXIGENCE

Phase NA Recruiting

12 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06328465 2026-01-06

fREEDOM

Phase NA Recruiting

145 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06418126 2026-01-05

TNBC-RT2023

Phase NA Active not recruiting

15 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06879704 2026-01-02

PRECISION

Phase NA Recruiting

115 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06349512 2025-12-22

FAP-IT

Phase NA Recruiting

60 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

EINSTEIN-TNBC

CROWN

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

NearWave Optical Molecular Monitoring

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

SCANDARE

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

CUPCAKE

WISH-OMICHIR

EXIGENCE

fREEDOM

TNBC-RT2023

PRECISION

FAP-IT